6533b7d1fe1ef96bd125c424
RESEARCH PRODUCT
Efficacy of Buffered Hypertonic Saline Nasal Irrigation for Nasal Symptoms in Children with Seasonal Allergic Rhinitis: A Randomized Controlled Trial
Donatella MarcheseGiovanni PassalacquaGiovanna CilluffoStefania La GruttaLaura MontalbanoGiuliana FerranteSalvatore FasolaMassimo LandiVelia Maliziasubject
MaleNeutrophilsmedicine.medical_treatmentSodium ChlorideGastroenterologylaw.inventionPittsburgh Sleep Quality IndexLeukocyte Count0302 clinical medicineQuality of lifeRandomized controlled triallawSurveys and QuestionnairesBuffered hypertonic solutionImmunology and AllergyChild030223 otorhinolaryngologyChildrenSalineHypertonicRhinitisNasal symptomGeneral MedicineNasal irrigationTreatment OutcomeNasal cytologyFemaleSaline SolutionNasal symptomsQuality of lifemedicine.medical_specialtyAdolescentSeasonal allergic rhinitisImmunology03 medical and health sciencesAllergicBuffered hypertonic solution; Children; Nasal cytology; Nasal symptoms; Quality of life; Seasonal allergic rhinitis; Adolescent; Child; Eosinophils; Female; Humans; Leukocyte Count; Male; Nasal Lavage; Neutrophils; Quality of Life; Rhinitis Allergic Seasonal; Saline Solution Hypertonic; Sodium Chloride; Surveys and Questionnaires; Treatment Outcome; Immunology and Allergy; ImmunologyInternal medicinemedicineHumansSaline Solution HypertonicSeasonalbusiness.industryRhinitis Allergic SeasonalNasal symptomsHypertonic salineEosinophils030228 respiratory systemNasal cytologyImmunologyNasal Lavagebusinessdescription
<b><i>Background:</i></b> Saline nasal irrigation is labelled as an add-on treatment in patients with allergic rhinitis (AR). The primary aim of this study was to compare the efficacy of 21-day use of buffered hypertonic saline (BHS) versus normal saline solution (NSS) on reducing nasal symptoms in children with seasonal AR (SAR). Comparing their efficacy on nasal cytology counts (NCC), quality of life, and sleep quality was the secondary aim. <b><i>Methods:</i></b> In this 21-day,<b> </b>open-label, randomized controlled study, 36 SAR children (aged 6-13 years) with a Total 5 Symptom Score (T5SS) ≥5 received twice-daily BHS or NSS delivered through a nasal douche. Efficacy measures were least square mean changes (LSmc) in T5SS, NCC, Paediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ), and Pittsburgh Sleep Quality Index (PSQI) scores. <b><i>Results:</i></b> BHS improved the T5SS total score to a greater extent than NSS (LSmc -6.45 vs. -5.45, <i>p</i> < 0.001). Concerning NCC, BHS significantly reduced the scores of neutrophils (LSmc -0.76, <i>p</i> = 0.004) and eosinophils (LSmc -0.46, <i>p</i> = 0.018), while NSS did not. Similarly, only BHS yielded a significant improvement in the PRQLQ score (LSmc -0.57, <i>p</i> = 0.009), whereas the improvement in PSQI score was comparable between the BHS (LSmc -0.77, <i>p</i> = 0.025) and NSS (LSmc -1.39, <i>p</i> < 0.001) groups. Overall, BHS was well tolerated. <b><i>Conclusions:</i></b> In children with SAR, BHS is effective in improving nasal symptoms and NCC, with an associated beneficial effect on quality of life.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2017-04-25 | International Archives of Allergy and Immunology |